Hansa Biopharma AB (publ) (HNSBF) Expected to Post Earnings on Wednesday

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) is expected to announce its resultson Wednesday, July 22nd. Analysts expect the company to post earnings of ($0.0346) per share and revenue of $5.17 million for the quarter.

Hansa Biopharma AB (publ) Stock Performance

HNSBF stock opened at $2.90 on Monday. Hansa Biopharma AB has a twelve month low of $2.90 and a twelve month high of $2.90. The firm’s fifty day simple moving average is $2.90 and its two-hundred day simple moving average is $2.90.

Analysts Set New Price Targets

Separately, Danske assumed coverage on shares of Hansa Biopharma AB (publ) in a research note on Tuesday, June 16th. They set a “buy” rating for the company. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hansa Biopharma AB (publ) presently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.